Durect's bupivicaine patch fails in Phase II on chronic back pain
This article was originally published in Scrip
Executive Summary
Durect Corp has reported top-line results that show that its investigational transdermal bipivacaine patch, Eladur, failed in a Phase II study focusing on chronic back pain.